HRP20120466T1 - Derivati indol ona disupstituirani na položaju njihovo dobivanje i upotreba u terapiji - Google Patents
Derivati indol ona disupstituirani na položaju njihovo dobivanje i upotreba u terapiji Download PDFInfo
- Publication number
- HRP20120466T1 HRP20120466T1 HRP20120466AT HRP20120466T HRP20120466T1 HR P20120466 T1 HRP20120466 T1 HR P20120466T1 HR P20120466A T HRP20120466A T HR P20120466AT HR P20120466 T HRP20120466 T HR P20120466T HR P20120466 T1 HRP20120466 T1 HR P20120466T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- alkyl
- general formula
- image
- group
- Prior art date
Links
- 150000005625 indol-2-ones Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 37
- 125000005843 halogen group Chemical group 0.000 claims abstract 23
- 125000003118 aryl group Chemical group 0.000 claims abstract 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract 16
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 8
- 125000001424 substituent group Chemical group 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 21
- 238000000034 method Methods 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- -1 CN Chemical group 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 208000027559 Appetite disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- JYNKNVRRALLCEQ-UHFFFAOYSA-N 2-chloro-n-[5-chloro-3-(2-chlorophenyl)-2-oxo-1h-indol-3-yl]acetamide Chemical compound O=C1NC2=CC=C(Cl)C=C2C1(NC(=O)CCl)C1=CC=CC=C1Cl JYNKNVRRALLCEQ-UHFFFAOYSA-N 0.000 claims 1
- AGTXDVTUPNSEBX-UHFFFAOYSA-N 3-(4-chlorophenyl)-3-[[2-(4-ethylpiperazin-1-yl)acetyl]amino]-2-oxo-4-(trifluoromethyl)-1h-indole-6-carboxamide Chemical compound C1CN(CC)CCN1CC(=O)NC1(C=2C=CC(Cl)=CC=2)C2=C(C(F)(F)F)C=C(C(N)=O)C=C2NC1=O AGTXDVTUPNSEBX-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- IMOAOGGERDRWGD-UHFFFAOYSA-N n-[1-benzoyl-5,6-dichloro-3-(4-chlorophenyl)-2-oxoindol-3-yl]-2-(4-methylpiperazin-1-yl)acetamide Chemical compound C1CN(C)CCN1CC(=O)NC1(C=2C=CC(Cl)=CC=2)C2=CC(Cl)=C(Cl)C=C2N(C(=O)C=2C=CC=CC=2)C1=O IMOAOGGERDRWGD-UHFFFAOYSA-N 0.000 claims 1
- GFIXDZZIFFKZKX-UHFFFAOYSA-N n-[3-(4-chlorophenyl)-6-cyano-2-oxo-4-(trifluoromethyl)-1h-indol-3-yl]-2-(4-ethylpiperazin-1-yl)acetamide Chemical compound C1CN(CC)CCN1CC(=O)NC1(C=2C=CC(Cl)=CC=2)C2=C(C(F)(F)F)C=C(C#N)C=C2NC1=O GFIXDZZIFFKZKX-UHFFFAOYSA-N 0.000 claims 1
- GZMQEEHRXAENQK-UHFFFAOYSA-N n-[4,6-dichloro-1-ethyl-3-(2-methyl-1-benzofuran-5-yl)-2-oxoindol-3-yl]-2-(4-ethylpiperazin-1-yl)acetamide Chemical compound C1=C(Cl)C=C(Cl)C2=C1N(CC)C(=O)C2(C=1C=C2C=C(C)OC2=CC=1)NC(=O)CN1CCN(CC)CC1 GZMQEEHRXAENQK-UHFFFAOYSA-N 0.000 claims 1
- NDTOLICHDNPBOX-UHFFFAOYSA-N n-[4,6-dichloro-2-oxo-3-[4-(trifluoromethoxy)phenyl]-1h-indol-3-yl]-2-(4-ethylpiperazin-1-yl)acetamide Chemical compound C1CN(CC)CCN1CC(=O)NC1(C=2C=CC(OC(F)(F)F)=CC=2)C2=C(Cl)C=C(Cl)C=C2NC1=O NDTOLICHDNPBOX-UHFFFAOYSA-N 0.000 claims 1
- CDQNSIHAOJRPEP-UHFFFAOYSA-N n-[4,6-dichloro-3-(3,4-dichlorophenyl)-2-oxo-1h-indol-3-yl]-2-(4-ethylpiperazin-1-yl)acetamide Chemical compound C1CN(CC)CCN1CC(=O)NC1(C=2C=C(Cl)C(Cl)=CC=2)C2=C(Cl)C=C(Cl)C=C2NC1=O CDQNSIHAOJRPEP-UHFFFAOYSA-N 0.000 claims 1
- QIADWBMYPDIXLX-UHFFFAOYSA-N n-[5-chloro-3-(2-chlorophenyl)-2-oxo-1h-indol-3-yl]-2-(4-methylpiperazin-1-yl)acetamide Chemical compound C1CN(C)CCN1CC(=O)NC1(C=2C(=CC=CC=2)Cl)C2=CC(Cl)=CC=C2NC1=O QIADWBMYPDIXLX-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004694 alkoxyaminocarbonyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0705858A FR2920023B1 (fr) | 2007-08-16 | 2007-08-16 | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique |
PCT/FR2008/001190 WO2009056707A2 (fr) | 2007-08-16 | 2008-08-14 | Dérivés de l'ind0l-2-0ne disubstitues en 3, leur preparation et leur application en thérapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120466T1 true HRP20120466T1 (hr) | 2012-07-31 |
Family
ID=39197313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120466AT HRP20120466T1 (hr) | 2007-08-16 | 2012-06-04 | Derivati indol ona disupstituirani na položaju njihovo dobivanje i upotreba u terapiji |
Country Status (42)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
FR2941946B1 (fr) * | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique |
FR2941947B1 (fr) * | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique |
CA2751834C (en) | 2009-02-13 | 2018-07-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CN108658836B (zh) * | 2018-05-15 | 2021-04-20 | 宁波大学 | 一种3-取代-3-叠氮基吲哚-2-酮类化合物的制备方法 |
EP3912625A1 (en) * | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2714378B1 (fr) * | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
AU5301199A (en) * | 1998-08-20 | 2000-03-14 | Sumitomo Pharmaceuticals Company, Limited | Oxindole derivatives as growth hormone releasers |
FR2827604B1 (fr) * | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
WO2005035498A1 (ja) * | 2003-10-08 | 2005-04-21 | Dainippon Sumitomo Pharma Co., Ltd. | 含窒素二環性化合物の摂食調節剤としての用途 |
-
2007
- 2007-08-16 FR FR0705858A patent/FR2920023B1/fr not_active Expired - Fee Related
-
2008
- 2008-08-14 MY MYPI2010000685A patent/MY149649A/en unknown
- 2008-08-14 WO PCT/FR2008/001190 patent/WO2009056707A2/fr active Application Filing
- 2008-08-14 CN CN200880103992.3A patent/CN103443076B/zh not_active Expired - Fee Related
- 2008-08-14 KR KR1020107003267A patent/KR20100051812A/ko active IP Right Grant
- 2008-08-14 RS RS20120207A patent/RS52321B/sr unknown
- 2008-08-14 BR BRPI0815171 patent/BRPI0815171A2/pt not_active Application Discontinuation
- 2008-08-14 AR ARP080103547A patent/AR067937A1/es unknown
- 2008-08-14 SI SI200830646T patent/SI2188253T1/sl unknown
- 2008-08-14 DK DK08845678.5T patent/DK2188253T3/da active
- 2008-08-14 JO JO2008376A patent/JO2749B1/en active
- 2008-08-14 ME MEP-2010-29A patent/ME00979B/me unknown
- 2008-08-14 EP EP08845678A patent/EP2188253B8/fr active Active
- 2008-08-14 AU AU2008320718A patent/AU2008320718B2/en not_active Ceased
- 2008-08-14 AT AT08845678T patent/ATE548349T1/de active
- 2008-08-14 UA UAA201002977A patent/UA101162C2/ru unknown
- 2008-08-14 NZ NZ583317A patent/NZ583317A/en not_active IP Right Cessation
- 2008-08-14 EA EA201070281A patent/EA019486B1/ru not_active IP Right Cessation
- 2008-08-14 MX MX2010001851A patent/MX2010001851A/es active IP Right Grant
- 2008-08-14 JP JP2010520610A patent/JP5685440B2/ja not_active Expired - Fee Related
- 2008-08-14 CA CA2696237A patent/CA2696237C/fr active Active
- 2008-08-14 ES ES08845678T patent/ES2384080T3/es active Active
- 2008-08-14 PE PE2008001384A patent/PE20090988A1/es not_active Application Discontinuation
- 2008-08-14 PT PT08845678T patent/PT2188253E/pt unknown
- 2008-08-14 PA PA20088793101A patent/PA8793101A1/es unknown
- 2008-08-14 PL PL08845678T patent/PL2188253T3/pl unknown
- 2008-08-15 UY UY31297A patent/UY31297A1/es not_active Application Discontinuation
- 2008-08-15 TW TW097131363A patent/TWI432423B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 TN TNP2010000025A patent/TN2010000025A1/fr unknown
- 2010-02-03 NI NI201000023A patent/NI201000023A/es unknown
- 2010-02-04 DO DO2010000050A patent/DOP2010000050A/es unknown
- 2010-02-05 CO CO10012804A patent/CO6251363A2/es not_active Application Discontinuation
- 2010-02-09 US US12/702,687 patent/US20100210662A1/en not_active Abandoned
- 2010-02-10 GT GT201000032A patent/GT201000032A/es unknown
- 2010-02-12 EC EC2010009961A patent/ECSP109961A/es unknown
- 2010-02-12 CR CR11273A patent/CR11273A/es unknown
- 2010-02-14 IL IL203956A patent/IL203956A/en not_active IP Right Cessation
- 2010-02-15 ZA ZA2010/01085A patent/ZA201001085B/en unknown
- 2010-02-16 HN HN2010000330A patent/HN2010000330A/es unknown
- 2010-03-08 MA MA32676A patent/MA31742B1/fr unknown
-
2011
- 2011-01-24 US US13/012,321 patent/US8202871B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 CY CY20121100490T patent/CY1112809T1/el unknown
- 2012-06-04 HR HRP20120466AT patent/HRP20120466T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120466T1 (hr) | Derivati indol ona disupstituirani na položaju njihovo dobivanje i upotreba u terapiji | |
RU2345070C2 (ru) | Производные аминоиндазолов в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции | |
JP4693787B2 (ja) | Cb1拮抗活性を有する1,3,5−三置換4,5−ジヒドロ−1h−ピラゾール誘導体 | |
CA2362381C (en) | Amide compounds and medicinal use thereof | |
RU2299200C2 (ru) | Производные 1н-имидазола, обладающие cb1-агонистической, частичной cb1-агонистической или cb1-антагонистической активностью | |
CA2456606C (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
CA2601980A1 (en) | 1-acetic acid-indole derivatives with pgd2 antagonist activity | |
JPH04270264A (ja) | セロトニン5ht▲1a▼アゴニスト | |
RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
WO2002012189A1 (fr) | Composes amide bicycliques condenses et utilisations medicales associees | |
NZ547319A (en) | use of CRTH2 antagonist compounds in therapy | |
TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
YU96103A (sh) | Novi derivati indola sa afinitetom za 5-ht6 receptor | |
TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
HRP20130004T1 (hr) | 4-supstituirani derivati fenoksifeniloctene kiseline | |
HUP0400343A2 (hu) | Ciklopropil-indol-származékok mint szelektív szerotonin-újrafelvétel inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
RU2007106180A (ru) | Производные индола, индазола или индолина | |
RU2005117783A (ru) | 1, 5-диарилпиррол-3-карбоксамидные производные и их применение в качестве модуляторов каннабиноидных рецепторов | |
JP2008542365A5 (sr) | ||
RU2007136783A (ru) | ГИДРАЗИНОКАРБОНИЛТИЕНО[2, 3-c]ПИРАЗОЛЫ, СПОСОБ ПОЛУЧЕНИЯ, СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ | |
JP2005532984A5 (sr) | ||
HUP0401883A2 (hu) | Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények | |
JP2005527521A5 (sr) | ||
RU2006122935A (ru) | Новые производные бензимидазола и имидазопиридина и их применение в качестве лекарственных средств | |
ZA200304913B (en) | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient. |